Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Agarwal Website

Piyush K. Agarwal, M.D.

Portait Photo of Piyush Agarwal
Urologic Oncology Branch
Head, Bladder Cancer Section
Investigator
Center for Cancer Research
National Cancer Institute
Building 10 - Hatfield CRC, Room 2-5952
Bethesda, MD 20892-1210
Phone:  
301-496-6353
Fax:  
301-402-0922
E-Mail:  
piyush.agarwal@nih.gov

Biography

Dr. Agarwal is a tenure-track investigator and the Head of the Bladder Cancer Section in the Urologic Oncology Branch of the National Cancer Institute, National Institutes of Health in Bethesda, MD. He received his M.D. from the Cornell (Weill) University School of Medicine in New York, New York. He then completed his urology residency at Case Western Reserve University in Cleveland, Ohio. He then went on to the University of Texas MD Anderson Cancer Center where he completed a fellowship in urologic oncology. Before coming to the NIH, Dr. Agarwal was a faculty member at the Henry Ford Hospital Vattikuti Urology Institute where he served as the Director of Robotic Bladder Surgery. Dr. Agarwal is a Board Certified and fellowship trained Urologic Oncologic Surgeon. Dr. Agarwal specializes in multidisciplinary management of bladder cancer and complex surgical techniques including robotic cystectomy and continent urinary diversions. He is also an expert in other urologic cancers including prostate, testicular, and penile carcinoma. His clinical and laboratory research focus on all aspects of bladder cancer, specifically, BCG-refractory disease and molecular targeted therapy.

Research

Dr. Agarwal is interested in targeted therapy for bladder cancer. One of his current projects include molecular targeted photoimmunotherapy in bladder cancer targeting EGFR, FGFR3, and other mutated and/or over-expressed surface receptors in urothelial cancer. This is in collaboration with Dr. Kobayashi and Dr. Choyke. In addition, he is starting a randomized phase I/II clinical trial for patients with high grade bladder cancer that have failed BCG that is looking at the efficacy of a vaccine combined with BCG. This is done in collaboration with Dr. Gulley and Dr. Schlom.

This page was last updated on 3/31/2014.